Q4 EPS Forecast for Bausch Health Cos Lifted by Analyst

Key Points

• Analysts at Zacks Research raised their Q4 2026 earnings per share estimate for Bausch Health Cos from $1.13 to $1.14.
• Wall Street Zen upgraded Bausch Health Cos to a "strong-buy" rating, reflecting increased investor confidence.
• Bausch Health Cos recently reported a net margin of 0.99% and a negative return on equity of 852.36%, indicating financial challenges despite revenue surpassing analyst expectations.

Bausch Health Cos Inc. (NYSE:BHC - Free Report) - Zacks Research boosted their Q4 2026 earnings per share estimates for Bausch Health Cos in a note issued to investors on Friday, September 26th. Zacks Research analyst Team now expects that the company will earn $1.14 per share for the quarter, up from their previous estimate of $1.13. The consensus estimate for Bausch Health Cos' current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos' Q1 2027 earnings at $0.88 EPS and FY2027 earnings at $4.38 EPS.

Bausch Health Cos (NYSE:BHC - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.97 by ($0.07). Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. The firm had revenue of $2.57 billion during the quarter, compared to analyst estimates of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS.

Separately, Wall Street Zen upgraded Bausch Health Cos from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 20th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Bausch Health Cos currently has a consensus rating of "Hold" and a consensus price target of $9.00.

Bausch Health Cos Price Performance

Bausch Health Cos stock opened at $6.49 on Monday. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of 24.96 and a beta of 0.48. The stock's 50 day moving average is $6.92 and its 200-day moving average is $6.06. Bausch Health Cos has a 12 month low of $4.25 and a 12 month high of $9.85.

Institutional Investors Weigh In On Bausch Health Cos

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cary Street Partners Financial LLC bought a new stake in Bausch Health Cos during the first quarter worth $27,000. SBI Securities Co. Ltd. lifted its stake in Bausch Health Cos by 244.2% during the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock worth $27,000 after purchasing an additional 3,001 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Bausch Health Cos during the first quarter worth $27,000. Russell Investments Group Ltd. increased its holdings in shares of Bausch Health Cos by 65.9% during the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company's stock worth $51,000 after buying an additional 3,106 shares in the last quarter. Finally, Wealthquest Corp acquired a new position in shares of Bausch Health Cos during the first quarter worth $58,000. 78.65% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Bausch Health Cos news, Director John Paulson bought 34,721,118 shares of the business's stock in a transaction on Thursday, August 14th. The stock was purchased at an average cost of $9.00 per share, for a total transaction of $312,490,062.00. Following the completion of the purchase, the director directly owned 70,755,869 shares of the company's stock, valued at approximately $636,802,821. This trade represents a 96.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders acquired 37,964,167 shares of company stock worth $333,757,793 in the last three months. 19.97% of the stock is owned by corporate insiders.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.